FDA Rains Down Criticism On Noven's Umbrella Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
DDMAC frowns on Noven Pharmaceuticals' attempt to bring together major depressive disorder and generalized anxiety disorder and claim that Pexeva (paroxetine mesylate) treats the combination.